The inhibitors of 17β-HSD10: are they any good?
Ernst Kwa, Charlene E. Ogilvie, Natalie C. Kormos, Alison J. E. Green, Terry K. Smith, Frank J. Gunn-Moore · 2026
Read The inhibitors of 17β-HSD10: are they any good? by Ernst Kwa, Charlene E. Ogilvie, Natalie C. Kormos, Alison J. E. Green, Terry K. Smith, Frank J. Gunn-Moore (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13250687.txt.
Description
Ernst Kwa and colleagues review drugs that block an enzyme called 17beta-HSD10 and ask whether any of them are truly useful. The enzyme sits in mitochondria, the energy centers of cells, and it is found at raised levels in the brains of people with Alzheimer's disease. Interest in it has grown as the first disease-modifying Alzheimer's treatments reach patients.
The review explains why the enzyme is a hard target: studies disagree about what it acts on inside the body. The authors sort through compounds that block its catalytic action and others that interfere with its separate roles. They weigh whether blocking the enzyme changes disease biology or mainly helps researchers probe metabolism in the living brain. Their verdict treats the inhibitors as promising research tools whose medical value is still unproven.
Catalog record
| CREATOR | Ernst Kwa, Charlene E. Ogilvie, Natalie C. Kormos, Alison J. E. Green, Terry K. Smith, Frank J. Gunn-Moore |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |